Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the ...
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.
Youths are most likely to smoke menthol cigarettes, but local grocer Tony Ahmed is pushing back against the trend.
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western studyFast Track Designation granted by FDA for CRB-701 to ...
JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering ...
Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed ...
Q4 2024 Earnings Call Transcript March 13, 2025 aTyr Pharma, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. Operator: Good afternoon, ladies and gentlemen, and ...
The Senate health committee announced Thursday morning that it was canceling a planned hearing on Weldon’s nomination because ...
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 4, 2025 – Santhera Pharmaceuticals (SI ...
Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback